AustralieFrV1, Main, Exploration, bibRecord, 007640

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Identifieur interne : 007640 ( Main/Exploration ); précédent : 007639; suivant : 007641

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Auteurs : David W. Miles [Royaume-Uni, Australie, Belgique, Espagne, France, Pologne, Corée du Sud, Canada, Italie, Allemagne, Suisse] ; Arlene Chan ; Luc Y. Dirix ; Javier Cortes ; Xavier Pivot ; Piotr Tomczak ; Thierry Delozier ; JOO HYUK SOHN ; Louise Provencher ; Fabio Puglisi ; Nadia Harbeck ; Guenther G. Steger ; Andreas Schneeweiss ; Andrew M. Wardley ; Andreas Chlistalla ; Gilles Romieu

Source :

Journal of clinical oncology [ 0732-183X ] ; 2010.

RBID : Pascal:10-0341551

Descripteurs français

Pascal (Inist)
- Essai clinique phase III, Etude comparative, Placebo, Bévacizumab, Stade avancé, Cancer du sein, Traitement de première intention, Cancérologie, Docétaxel, Métastase, Facteur croissance endothélium vasculaire, Anticancéreux, Antiangiogénique, Récepteur HER2.

English descriptors

KwdEn :
- Advanced stage, Antiangiogenic agent, Antineoplastic agent, Bevacizumab, Breast cancer, Cancerology, Comparative study, Docetaxel, First line treatment, Human Epidermal growth factor Receptor 2, Metastasis, Phase III trial, Placebo, Vascular endothelium growth factor.

Abstract

Purpose The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial. Patients and Methods Patients (N = 736) were randomly assigned to docetaxel 100 mg/m² plus either placebo or bevacizumab 7.5 or 15 mg/kg every 3 weeks. The primary end point was progression-free survival (PFS); secondary end points included best overall response, duration of response, time to treatment failure, overall survival, and safety. Results Combination of bevacizumab 15 mg/kg, but not 7.5 mg/kg, with docetaxel showed superior median PFS (mPFS) to placebo plus docetaxel in unstratified analysis (placebo mPFS, 8.2 months; 7.5 mg/kg mPFS, 9.0 months [hazard ratio (HR), 0.86; P = .12]; 15 mg/kg mPFS, 10.1 months [HR, 0.77; P = .006]) and stratified analysis (placebo mPFS, 8.1 months; 7.5 mg/kg mPFS, 9.0 months [HR, 0.80; P = .045]; 15 mg/kg mPFS, 10.0 months [HR, 0.67; P < .001]). Response rates in patients with measurable disease at baseline also increased with bevacizumab 15 mg/kg (46% [placebo] ν 55% [7.5 mg/kg; P ₌ .07] and 64% [15 mg/kg; P < .001]). Combination with bevacizumab had limited impact on the known toxicity profile of docetaxel. Conclusion Combination of bevacizumab with docetaxel did not significantly impact on the safety profile of docetaxel. Bevacizumab 15 mg/kg every 3 weeks significantly increased PFS when combined with docetaxel as first-line therapy for MBC compared with docetaxel plus placebo.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 002530
to stream PascalFrancis, to step Curation: 003A56
to stream PascalFrancis, to step Checkpoint: 002154
to stream Main, to step Merge: 007C22
to stream Main, to step Curation: 007640

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer</title>
<author><name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Mount Vernon Cancer Centre</s1>
<s2>Middlesex</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Mount Vernon Cancer Centre</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mount Hospital, Mount Breast Group</s1>
<s2>Perth</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Perth</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Algemeen Ziekenhuis St Augustinus Oncology</s1>
<s2>Wilrijk</s2>
<s3>BEL</s3>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Algemeen Ziekenhuis St Augustinus Oncology</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>University Hospital Vall d'Hebron Oncology</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
</inist:fA14>
<country>Espagne</country>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>University Hospital of Besançon, Besançon; Centre Francois Baclesse</s1>
<s2>Caen</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Région Normandie</region>
<region type="old region">Basse-Normandie</region>
<settlement type="city">Caen</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>CRLCC Val d'Aurelle, P. Lamarque Service Chimioimmunotherapie</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Klinika Onkologii Oddzial Chemioterapii</s1>
<s2>Poznań</s2>
<s3>POL</s3>
</inist:fA14>
<country>Pologne</country>
<wicri:noRegion>Klinika Onkologii Oddzial Chemioterapii</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Yonsei Uni College of Medicine</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
</inist:fA14>
<country>Corée du Sud</country>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Centre des Maladies du Sein Deschênes-Fabia</s1>
<s2>Quebec City</s2>
<s3>CAN</s3>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Centre des Maladies du Sein Deschênes-Fabia</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>University Hospital of Udine</s1>
<s2>Udine</s2>
<s3>ITA</s3>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>University Hospital of Udine</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="11"><s1>Frauenklinik der Technischen Universität München</s1>
<s3>DEU</s3>
</inist:fA14>
<country>Allemagne</country>
<placeName><settlement type="city">Munich</settlement>
<region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
</placeName>
<orgName type="university">Université Louis-et-Maximilien de Munich</orgName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="12"><s1>Medical University of Vienna, Vienna, Austria; University of Heidelberg</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Cancer Research UK, The Christie</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>F. Hoffmann-La Roche Ltd, Pharmaceutical Division</s1>
<s2>Basel</s2>
<s3>CHE</s3>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name>
</author>
<author><name sortKey="Dirix, Luc Y" sort="Dirix, Luc Y" uniqKey="Dirix L" first="Luc Y." last="Dirix">Luc Y. Dirix</name>
</author>
<author><name sortKey="Cortes, Javier" sort="Cortes, Javier" uniqKey="Cortes J" first="Javier" last="Cortes">Javier Cortes</name>
</author>
<author><name sortKey="Pivot, Xavier" sort="Pivot, Xavier" uniqKey="Pivot X" first="Xavier" last="Pivot">Xavier Pivot</name>
</author>
<author><name sortKey="Tomczak, Piotr" sort="Tomczak, Piotr" uniqKey="Tomczak P" first="Piotr" last="Tomczak">Piotr Tomczak</name>
</author>
<author><name sortKey="Delozier, Thierry" sort="Delozier, Thierry" uniqKey="Delozier T" first="Thierry" last="Delozier">Thierry Delozier</name>
</author>
<author><name sortKey="Joo Hyuk Sohn" sort="Joo Hyuk Sohn" uniqKey="Joo Hyuk Sohn" last="Joo Hyuk Sohn">JOO HYUK SOHN</name>
</author>
<author><name sortKey="Provencher, Louise" sort="Provencher, Louise" uniqKey="Provencher L" first="Louise" last="Provencher">Louise Provencher</name>
</author>
<author><name sortKey="Puglisi, Fabio" sort="Puglisi, Fabio" uniqKey="Puglisi F" first="Fabio" last="Puglisi">Fabio Puglisi</name>
</author>
<author><name sortKey="Harbeck, Nadia" sort="Harbeck, Nadia" uniqKey="Harbeck N" first="Nadia" last="Harbeck">Nadia Harbeck</name>
</author>
<author><name sortKey="Steger, Guenther G" sort="Steger, Guenther G" uniqKey="Steger G" first="Guenther G." last="Steger">Guenther G. Steger</name>
</author>
<author><name sortKey="Schneeweiss, Andreas" sort="Schneeweiss, Andreas" uniqKey="Schneeweiss A" first="Andreas" last="Schneeweiss">Andreas Schneeweiss</name>
</author>
<author><name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
</author>
<author><name sortKey="Chlistalla, Andreas" sort="Chlistalla, Andreas" uniqKey="Chlistalla A" first="Andreas" last="Chlistalla">Andreas Chlistalla</name>
</author>
<author><name sortKey="Romieu, Gilles" sort="Romieu, Gilles" uniqKey="Romieu G" first="Gilles" last="Romieu">Gilles Romieu</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0341551</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0341551 INIST</idno>
<idno type="RBID">Pascal:10-0341551</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002530</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003A56</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002154</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002154</idno>
<idno type="wicri:doubleKey">0732-183X:2010:Miles D:phase:iii:study</idno>
<idno type="wicri:Area/Main/Merge">007C22</idno>
<idno type="wicri:Area/Main/Curation">007640</idno>
<idno type="wicri:Area/Main/Exploration">007640</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer</title>
<author><name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Mount Vernon Cancer Centre</s1>
<s2>Middlesex</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Mount Vernon Cancer Centre</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mount Hospital, Mount Breast Group</s1>
<s2>Perth</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Perth</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Algemeen Ziekenhuis St Augustinus Oncology</s1>
<s2>Wilrijk</s2>
<s3>BEL</s3>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Algemeen Ziekenhuis St Augustinus Oncology</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>University Hospital Vall d'Hebron Oncology</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
</inist:fA14>
<country>Espagne</country>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>University Hospital of Besançon, Besançon; Centre Francois Baclesse</s1>
<s2>Caen</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Région Normandie</region>
<region type="old region">Basse-Normandie</region>
<settlement type="city">Caen</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>CRLCC Val d'Aurelle, P. Lamarque Service Chimioimmunotherapie</s1>
<s2>Montpellier</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Klinika Onkologii Oddzial Chemioterapii</s1>
<s2>Poznań</s2>
<s3>POL</s3>
</inist:fA14>
<country>Pologne</country>
<wicri:noRegion>Klinika Onkologii Oddzial Chemioterapii</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Yonsei Uni College of Medicine</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
</inist:fA14>
<country>Corée du Sud</country>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Centre des Maladies du Sein Deschênes-Fabia</s1>
<s2>Quebec City</s2>
<s3>CAN</s3>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Centre des Maladies du Sein Deschênes-Fabia</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>University Hospital of Udine</s1>
<s2>Udine</s2>
<s3>ITA</s3>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>University Hospital of Udine</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="11"><s1>Frauenklinik der Technischen Universität München</s1>
<s3>DEU</s3>
</inist:fA14>
<country>Allemagne</country>
<placeName><settlement type="city">Munich</settlement>
<region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
</placeName>
<orgName type="university">Université Louis-et-Maximilien de Munich</orgName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="12"><s1>Medical University of Vienna, Vienna, Austria; University of Heidelberg</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Cancer Research UK, The Christie</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>F. Hoffmann-La Roche Ltd, Pharmaceutical Division</s1>
<s2>Basel</s2>
<s3>CHE</s3>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name>
</author>
<author><name sortKey="Dirix, Luc Y" sort="Dirix, Luc Y" uniqKey="Dirix L" first="Luc Y." last="Dirix">Luc Y. Dirix</name>
</author>
<author><name sortKey="Cortes, Javier" sort="Cortes, Javier" uniqKey="Cortes J" first="Javier" last="Cortes">Javier Cortes</name>
</author>
<author><name sortKey="Pivot, Xavier" sort="Pivot, Xavier" uniqKey="Pivot X" first="Xavier" last="Pivot">Xavier Pivot</name>
</author>
<author><name sortKey="Tomczak, Piotr" sort="Tomczak, Piotr" uniqKey="Tomczak P" first="Piotr" last="Tomczak">Piotr Tomczak</name>
</author>
<author><name sortKey="Delozier, Thierry" sort="Delozier, Thierry" uniqKey="Delozier T" first="Thierry" last="Delozier">Thierry Delozier</name>
</author>
<author><name sortKey="Joo Hyuk Sohn" sort="Joo Hyuk Sohn" uniqKey="Joo Hyuk Sohn" last="Joo Hyuk Sohn">JOO HYUK SOHN</name>
</author>
<author><name sortKey="Provencher, Louise" sort="Provencher, Louise" uniqKey="Provencher L" first="Louise" last="Provencher">Louise Provencher</name>
</author>
<author><name sortKey="Puglisi, Fabio" sort="Puglisi, Fabio" uniqKey="Puglisi F" first="Fabio" last="Puglisi">Fabio Puglisi</name>
</author>
<author><name sortKey="Harbeck, Nadia" sort="Harbeck, Nadia" uniqKey="Harbeck N" first="Nadia" last="Harbeck">Nadia Harbeck</name>
</author>
<author><name sortKey="Steger, Guenther G" sort="Steger, Guenther G" uniqKey="Steger G" first="Guenther G." last="Steger">Guenther G. Steger</name>
</author>
<author><name sortKey="Schneeweiss, Andreas" sort="Schneeweiss, Andreas" uniqKey="Schneeweiss A" first="Andreas" last="Schneeweiss">Andreas Schneeweiss</name>
</author>
<author><name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
</author>
<author><name sortKey="Chlistalla, Andreas" sort="Chlistalla, Andreas" uniqKey="Chlistalla A" first="Andreas" last="Chlistalla">Andreas Chlistalla</name>
</author>
<author><name sortKey="Romieu, Gilles" sort="Romieu, Gilles" uniqKey="Romieu G" first="Gilles" last="Romieu">Gilles Romieu</name>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>Antiangiogenic agent</term>
<term>Antineoplastic agent</term>
<term>Bevacizumab</term>
<term>Breast cancer</term>
<term>Cancerology</term>
<term>Comparative study</term>
<term>Docetaxel</term>
<term>First line treatment</term>
<term>Human Epidermal growth factor Receptor 2</term>
<term>Metastasis</term>
<term>Phase III trial</term>
<term>Placebo</term>
<term>Vascular endothelium growth factor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Essai clinique phase III</term>
<term>Etude comparative</term>
<term>Placebo</term>
<term>Bévacizumab</term>
<term>Stade avancé</term>
<term>Cancer du sein</term>
<term>Traitement de première intention</term>
<term>Cancérologie</term>
<term>Docétaxel</term>
<term>Métastase</term>
<term>Facteur croissance endothélium vasculaire</term>
<term>Anticancéreux</term>
<term>Antiangiogénique</term>
<term>Récepteur HER2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial. Patients and Methods Patients (N = 736) were randomly assigned to docetaxel 100 mg/m<sup>2</sup>
 plus either placebo or bevacizumab 7.5 or 15 mg/kg every 3 weeks. The primary end point was progression-free survival (PFS); secondary end points included best overall response, duration of response, time to treatment failure, overall survival, and safety. Results Combination of bevacizumab 15 mg/kg, but not 7.5 mg/kg, with docetaxel showed superior median PFS (mPFS) to placebo plus docetaxel in unstratified analysis (placebo mPFS, 8.2 months; 7.5 mg/kg mPFS, 9.0 months [hazard ratio (HR), 0.86; P = .12]; 15 mg/kg mPFS, 10.1 months [HR, 0.77; P = .006]) and stratified analysis (placebo mPFS, 8.1 months; 7.5 mg/kg mPFS, 9.0 months [HR, 0.80; P = .045]; 15 mg/kg mPFS, 10.0 months [HR, 0.67; P < .001]). Response rates in patients with measurable disease at baseline also increased with bevacizumab 15 mg/kg (46% [placebo] ν 55% [7.5 mg/kg; P <sub>=</sub>
 .07] and 64% [15 mg/kg; P < .001]). Combination with bevacizumab had limited impact on the known toxicity profile of docetaxel. Conclusion Combination of bevacizumab with docetaxel did not significantly impact on the safety profile of docetaxel. Bevacizumab 15 mg/kg every 3 weeks significantly increased PFS when combined with docetaxel as first-line therapy for MBC compared with docetaxel plus placebo.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Belgique</li>
<li>Canada</li>
<li>Corée du Sud</li>
<li>Espagne</li>
<li>France</li>
<li>Italie</li>
<li>Pologne</li>
<li>Royaume-Uni</li>
<li>Suisse</li>
</country>
<region><li>Angleterre</li>
<li>Bade-Wurtemberg</li>
<li>Basse-Normandie</li>
<li>Bavière</li>
<li>Catalogne</li>
<li>District de Haute-Bavière</li>
<li>District de Karlsruhe</li>
<li>Grand Manchester</li>
<li>Languedoc-Roussillon</li>
<li>Occitanie (région administrative)</li>
<li>Région Normandie</li>
<li>Région capitale de Séoul</li>
</region>
<settlement><li>Barcelone</li>
<li>Caen</li>
<li>Heidelberg</li>
<li>Manchester</li>
<li>Montpellier</li>
<li>Munich</li>
<li>Séoul</li>
</settlement>
<orgName><li>Université Louis-et-Maximilien de Munich</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name>
<name sortKey="Chlistalla, Andreas" sort="Chlistalla, Andreas" uniqKey="Chlistalla A" first="Andreas" last="Chlistalla">Andreas Chlistalla</name>
<name sortKey="Cortes, Javier" sort="Cortes, Javier" uniqKey="Cortes J" first="Javier" last="Cortes">Javier Cortes</name>
<name sortKey="Delozier, Thierry" sort="Delozier, Thierry" uniqKey="Delozier T" first="Thierry" last="Delozier">Thierry Delozier</name>
<name sortKey="Dirix, Luc Y" sort="Dirix, Luc Y" uniqKey="Dirix L" first="Luc Y." last="Dirix">Luc Y. Dirix</name>
<name sortKey="Harbeck, Nadia" sort="Harbeck, Nadia" uniqKey="Harbeck N" first="Nadia" last="Harbeck">Nadia Harbeck</name>
<name sortKey="Joo Hyuk Sohn" sort="Joo Hyuk Sohn" uniqKey="Joo Hyuk Sohn" last="Joo Hyuk Sohn">JOO HYUK SOHN</name>
<name sortKey="Pivot, Xavier" sort="Pivot, Xavier" uniqKey="Pivot X" first="Xavier" last="Pivot">Xavier Pivot</name>
<name sortKey="Provencher, Louise" sort="Provencher, Louise" uniqKey="Provencher L" first="Louise" last="Provencher">Louise Provencher</name>
<name sortKey="Puglisi, Fabio" sort="Puglisi, Fabio" uniqKey="Puglisi F" first="Fabio" last="Puglisi">Fabio Puglisi</name>
<name sortKey="Romieu, Gilles" sort="Romieu, Gilles" uniqKey="Romieu G" first="Gilles" last="Romieu">Gilles Romieu</name>
<name sortKey="Schneeweiss, Andreas" sort="Schneeweiss, Andreas" uniqKey="Schneeweiss A" first="Andreas" last="Schneeweiss">Andreas Schneeweiss</name>
<name sortKey="Steger, Guenther G" sort="Steger, Guenther G" uniqKey="Steger G" first="Guenther G." last="Steger">Guenther G. Steger</name>
<name sortKey="Tomczak, Piotr" sort="Tomczak, Piotr" uniqKey="Tomczak P" first="Piotr" last="Tomczak">Piotr Tomczak</name>
<name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
</noCountry>
<country name="Royaume-Uni"><noRegion><name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
</noRegion>
<name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
</country>
<country name="Australie"><noRegion><name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
</noRegion>
</country>
<country name="Belgique"><noRegion><name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
</noRegion>
</country>
<country name="Espagne"><region name="Catalogne"><name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
</region>
</country>
<country name="France"><region name="Région Normandie"><name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
</region>
<name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
</country>
<country name="Pologne"><noRegion><name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
</noRegion>
</country>
<country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
</region>
</country>
<country name="Canada"><noRegion><name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
</noRegion>
</country>
<country name="Italie"><noRegion><name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
</noRegion>
</country>
<country name="Allemagne"><region name="Bavière"><name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
</region>
<name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
</country>
<country name="Suisse"><noRegion><name sortKey="Miles, David W" sort="Miles, David W" uniqKey="Miles D" first="David W." last="Miles">David W. Miles</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007640 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 007640 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:10-0341551
   |texte=   Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri